Author/Authors :
Sahin, Hatice Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Gok Oguz, Ebru Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Akoglu, Hadim Department of Nephrology - Health Science University Gulhane Training and Research Hospital, Ankara, Turkey , Atilgan, Gokhan Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Ulusal Okyay, Gulay Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Karaveli Gursoy, Guner Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Kip Teymur, Tuğba Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Ertoy, Dilek Department of Pathology - Hacettepe University, Ankara, Turkey , Canbakan, Basol Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey , Deniz Ayli, Mehmet Diskapi Yildirim Beyazit Education and Research Hospital - Department of Nephrology, Ankara, Turkey
Abstract :
Two-thirds of complement C3 glomerulopathy (C3G) recur after transplantation and commonly cause graft loss. There is not a standard treatment protocol for these cases. We present a kidney transplant patient with recurrent C3G who was successfully treated with eculizumab. Nephrotic proteinuria and hematuria occurred and creatinine levels increased after transplantation. A graft biopsy revealed recurrent C3G. The patient was administered 250 mg pulse methylprednisolone for 3 days and had 9 sessions of plasmapheresis. Since elevated creatinine levels and proteinuria persisted, eculizumab was instituted. A complete remission was observed after 9-month maintenance eculizumab treatment. Eculizumab may be a potentially effective option in kidney transplant patients with recurrent C3G unresponsive to other treatment modalities.
